FOXD4L6

Across TCGA pan-cancer cohorts, FOXD4L6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FOXD4L6 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FOXD4L6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FOXD4L6 expression acts as an unfavorable survival marker.

HNSC, COAD, and LUSC are the cancer types where FOXD4L6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.195	0.710	.019	15	view →
COAD	DFS	Median	All	0.140	0.781	<.001	9	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FOXD4L6–HNSC (DFS)

Open the HNSC breakdown →